Aquestive Therapeutics, Inc. (AQST) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — AQST

Balance Sheet

(in millions USD)

Metric	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	110.73	129.06	60.54	68.66	77.89	89.87	95.20	24.92	22.44	26.88	18.65	17.70	14.74	31.16	34.23	27.50
Accounts Receivable	6.87	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Inventory	8.07	7.88	8.13	7.20	7.02	6.97	7.73	7.08	5.95	6.98	6.73	5.01	4.63	2.86	2.84	2.80
Total Current Assets	130.18	151.67	81.72	89.17	96.57	104.01	113.38	42.46	39.79	43.71	38.09	43.51	42.59	50.21	51.00	44.44
Property, Plant & Equipment	3.84	3.92	3.86	3.80	3.85	3.92	4.05	4.55	4.60	3.81	4.28	4.57	4.50	5.20	5.79	6.28
Intangible Assets	--	0.00	0.00	0.00	0.00	0.00	1.24	1.32	1.36	1.40	1.49	0.03	0.04	0.06	0.08	0.09
Total Non-current Assets*	10.94	11.89	11.98	13.07	13.39	13.59	16.14	16.99	17.21	17.58	13.76	12.81	13.94	15.08	15.88	17.48
Total Assets	141.13	163.56	93.70	102.23	109.96	117.61	129.52	59.45	56.99	61.29	51.85	56.31	56.53	65.29	66.88	61.92
Accounts Payable	11.89	10.87	11.95	12.28	7.57	5.70	10.52	9.99	10.69	12.44	11.07	8.89	8.50	6.22	8.10	6.37
Total Current Liabilities	31.75	25.57	23.16	18.30	15.15	13.90	18.06	24.06	38.65	40.38	36.56	29.64	24.18	25.04	23.04	20.05
Long-term Debt	45.00	45.00	45.00	45.00	45.00	45.00	45.00	38.98	38.98	42.41	51.50	51.50	51.50	51.50	51.50	51.50
Total Non-current Liabilities*	143.43	142.09	143.13	144.87	140.23	139.19	147.77	138.32	124.99	130.14	123.10	123.03	125.49	100.60	97.61	93.67
Total Liabilities	175.18	167.67	166.29	163.16	155.38	153.08	165.82	162.38	163.65	170.52	159.66	152.67	149.67	125.64	120.64	113.72
Retained Earnings	(455.05)	(415.14)	(399.69)	(386.14)	(346.16)	(334.65)	(331.90)	(310.97)	(308.93)	(303.14)	(298.85)	(286.32)	(270.02)	(227.85)	(213.30)	(200.93)
Total Stockholder Equity	(34.05)	(4.11)	(72.59)	(60.93)	(45.42)	(35.48)	(36.30)	(102.93)	(106.65)	(109.23)	(107.82)	(96.36)	(93.14)	(60.34)	(53.77)	(51.80)

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Total Revenue	14.45	13.02	12.81	10.00	8.72	11.87	13.54	20.10	12.05	13.21	13.00	13.24	11.13	10.68	11.46	13.27	12.27	11.08	13.29	15.35
Cost of Revenue*	3.47	5.84	4.51	4.56	3.65	4.52	4.44	4.53	4.39	4.68	4.80	6.62	4.74	5.31	4.63	5.24	4.21	--	4.40	4.47
Gross Profit	10.98	7.18	8.30	5.44	5.07	7.35	9.11	15.57	7.66	8.53	8.20	6.62	6.40	5.38	6.84	8.02	8.06	--	8.89	10.88
Research & Development	4.20	3.20	4.53	4.11	5.36	4.92	5.27	4.16	5.93	2.89	3.20	3.47	3.55	4.28	3.23	5.20	4.77	4.40	4.73	4.26
Selling, General & Admin	10.98	32.82	15.25	12.71	19.07	16.01	12.13	11.36	10.69	9.55	7.39	7.36	7.46	11.81	12.46	15.59	13.02	14.98	12.13	13.13
Total Operating Expenses	15.18	36.02	19.78	16.81	24.43	20.93	17.40	15.52	16.62	12.44	10.58	10.83	11.00	35.48	15.69	20.79	17.79	34.37	16.86	17.40
Operating Income	(4.20)	(28.84)	(11.48)	(11.37)	(19.36)	(13.58)	(8.29)	0.06	(8.96)	(3.91)	(2.38)	(4.21)	(4.61)	(10.71)	(8.85)	(12.76)	(9.74)	(11.67)	(7.97)	(6.52)
Interest Expense	--	--	--	--	--	--	--	2.78	2.78	2.27	1.26	1.37	1.44	1.65	1.65	1.64	1.62	1.74	2.79	2.76
Pretax Income	(8.06)	(31.86)	(15.45)	(13.55)	(22.93)	(17.07)	(11.51)	(2.74)	(12.83)	(8.01)	(2.17)	(5.51)	8.07	(12.35)	(12.54)	(16.30)	(13.22)	(28.94)	(14.55)	(12.37)
Tax Provision	0.00	0.00	0.00	0.00	0.00	(0.01)	0.00	0.00	0.00	0.10	(0.14)	0.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	(8.06)	(31.86)	(15.45)	(13.55)	(22.93)	(17.05)	(11.51)	(2.74)	(12.83)	(8.11)	(2.03)	(5.79)	8.07	(12.35)	(12.54)	(16.30)	(13.22)	(28.94)	(14.55)	(12.37)
Basic EPS	(0.07)	(0.26)	(0.14)	(0.14)	(0.24)	(0.18)	(0.13)	(0.03)	(0.17)	(0.15)	(0.03)	(0.10)	0.15	(0.21)	(0.23)	(0.36)	(0.32)	(0.74)	(0.37)	(0.33)
Diluted EPS	(0.07)	(0.26)	(0.14)	(0.14)	(0.24)	(0.18)	(0.13)	(0.03)	(0.17)	(0.11)	(0.03)	(0.10)	0.11	(0.21)	(0.23)	(0.36)	(0.32)	(0.74)	(0.37)	(0.33)

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Operating Cash Flow	(14.81)	(8.47)	(12.65)	(7.91)	(23.40)	(6.49)	(11.88)	(7.01)	(10.38)	(4.94)	(2.35)	(7.91)	8.82	8.45	2.81	(6.56)	(14.48)	(8.06)	(9.06)	(1.76)
Capital Expenditures	0.05	0.09	0.24	0.11	0.14	0.02	0.08	0.04	0.03	0.02	0.15	0.83	0.00	0.03	0.22	0.68	0.10	0.53	0.08	0.19
Free Cash Flow*	(14.86)	(8.55)	(12.88)	(8.02)	(23.53)	(6.50)	(11.96)	(7.04)	(10.41)	(4.96)	(2.50)	(8.73)	8.81	8.42	2.59	(7.24)	(14.59)	(8.59)	(9.15)	(1.95)
Investing Cash Flow	(0.05)	(0.08)	(0.23)	(0.11)	(0.13)	(0.01)	(0.08)	(0.04)	(0.03)	(0.02)	(0.15)	(0.83)	-0.00	(0.03)	(1.72)	(0.68)	(0.10)	(0.53)	(0.08)	(0.19)
Financing Cash Flow	4.42	0.66	81.41	(0.10)	20.65	0.16	(0.02)	1.71	81.74	3.91	4.98	4.29	(9.20)	0.20	(0.14)	10.20	1.30	5.45	6.08	8.69

* Derived from reported values